drugset / Trial / NCT04329130
Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this open label,single arm,phase Ⅱ clinical trail is to determine the safety and efficacy of Chidamide combination with lenalidomide for relapsed or refractory peripheral T-cell lymphoma.
Timeline
- Start
- 2020-03-27
- Primary completion
- 2022-03-26
- Completion
- 2025-03-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 25 mg | — |
| Subject | Tucidinostat | Small molecule | 20 mg | Oral |